Table 3 Shivering profile in the studied groups

Incidence of shivering; n, %

38 (38.0%) a

64 (64.0%) b

89 (89.0%) c

#< 0.001*

RR

95% CI

0.59

(0.44–0.79)

0.43

(0.33–0.55)

0.72

(0.61–0.85)

 • 0

62 (62.0%) a

36 (36.0%) b

11 (11.0%) c

#< 0.001*

 • I

23 (23.0%) a

24 (24.0%) a

12 (12.0%) a

 • II

10 (10.0%) a

24 (24.0%) b

45 (45.0%) c

 • III

5 (5.0%) a

16 (16).0% b

32 (32.0%) c

Patients in need for anti-shivering treatment (Grades 2 and 3); n, %

15 (15.0%) a

40 (40.0%) b

77 (77.0%) c

#< 0.001*

RR

95% CI

0.38

(0.22–0.63)

0.19

(0.12–0.31)

0.52

(0.40–0.68)

Onset of Shivering; (min)

67.7 (2.5) a

33.9 (2.9) b

16.6 (2.4) c

^< 0.001*

M (SE)

95% CI

33.8 (0.6)

32.7–35.0

51.2 (0.5)

50.2–52.1

17.3 (0.4)

16.5–18.2

Meperidine dose; (mg)

25.0 (0) a

32.5 (11.6) b

39.9 (12.3) c

^< 0.001*

M (SE)

95% CI

−7.5 (3)

−13.5–-1.5

−14.9 (3.2)

−21.3–-8.6

−7.4 (2.4)

−12.1–-2.8

Response rate; n, %

15 (100.0%) a

28 (70.0%) b

31 (40.3%) c

#< 0.001*

RR

(95% CI)

Not applicable

Not applicable

1.74

(1.24–2.44)

Recurrence; n, %

0 (0.0%) a

12 (30.0%) b

46 (59.7%) c

#< 0.001*

RR

95% CI

Not applicable

Not applicable

0.5

(0.30–0.83)